USPTO serial 88718586
AGOS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 11, 2021
- Examiner
- REID, CAILE MAUREEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with AGOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,295*
Plus Government fees of $1,625
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard M. LaBarge
Richard M. LaBarge MARSHALL, GERSTEIN & BORUN LLP233 SOUTH WACKER DRIVE, SUITE 6300CHICAGO, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable and recorded computer software for use as a database and for analysing data in the fields of pharmaceuticals, clinical trials, clinical research and biotechnology; Downloadable software applications for computers, laptops and mobile phones featuring software for use as a database and for collating, storing, analysing, and utilizing data in the fields of pharmaceuticals, clinical trials, clinical research and biotechnology; Downloadable and recorded software for secure data storage and retrieval and transmission of customer and client information; Downloadable and recorded computer software for use as a database and for collating, storing, analysing and utilizing data in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; downloadable and recorded computer operating programs and downloadable and recorded application development software for use on or in connection with mobile phones, tablets and handheld devices in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; data processing equipment and computers; Downloadable electronic publications in the nature of e-books, magazines, newsletters and reports provided on-line from a database or the internet in the fields of pharmaceuticals, clinical trials, clinical research and biotechnology | ACTIVE | — |
| 035 | Business project and risk management services in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; business consultancy services; Business project and risk management and consultancy services in the field of clinical trials and clinical research; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management services for medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; providing business information management services on clinical trials and clinical research; providing business intelligence services in the fields of medical devices, pharmaceuticals and the life sciences; providing business management information in connection with consultancy and advisory services in the field of strategic planning; regulatory submission management, namely, business strategic planning, and preparing and submitting applications for others for new medical devices, new pharmaceuticals, variations on previously approved medical devices, and variations on previously approved pharmaceuticals to receive clinical trial approval or marketing authorization from governmental regulatory bodies; regulatory submission management, namely, assisting others with strategic business planning, and preparing and filing applications with governmental regulatory bodies for approval of new medical devices and new pharmaceuticals; Regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; New pharmaceutical and biotechnology product commercialization services; consultancy services for others in the field of new pharmaceutical and biotechnology product commercialization; information, advice and consultancy services in relation to all the aforesaid services | ACTIVE | — |
| 038 | Providing Internet access, namely, providing access to platforms and portals on the internet in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; providing user access to global computer networks, namely, providing user access to platforms and portals on the internet in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; information, advice and consultancy services in relation to all the aforesaid services | ACTIVE | — |
| 042 | Providing medical and scientific research information in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; Product and scientific research and development in the field of pharmaceuticals, clinical trials, clinical research, medical devices and biotechnology; Consultancy services for others in the field of technical consultancy for pharmaceuticals, design, planning, and implementation consultancy for clinical trials, consultancy on scientific clinical research, and design and development consultancy for medical devices; conducting early evaluations in the field of new pharmaceuticals; consultancy services in the field of design, planning, implementation and project management of clinical trials, pharmacovigilance, pharmaceutical and biotechnology product development; consultancy services in the fields of biotechnology, pharmaceutical research and development, laboratory testing and pharmacogenetics; medical and scientific research; conducting clinical trials for others; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; product development consultancy in the field of pharmaceuticals and biotechnology; testing and quality control evaluation of products in the field of pharmaceuticals, clinical trials and biotechnology; product testing and quality control evaluation of pharmaceutical preparations and medicines; testing and quality control in the nature of conducting clinical trials in the field of pharmaceuticals and biotechnology for others; Software as a Service (SaaS) featuring software for use as a database and for analysing data in the fields of in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; providing online non-downloadable software applications for use in creating, designing, hosting, publishing, managing and maintaining content for use on the internet for website and media content management purposes; application service provider featuring application programming interface (API) software to allow people to view data through an interactive map, to query data, to generate reports and to access data and documents; software as a service (SAAS) featuring computer software to enable the displaying, receiving and transmitting of data to enable the purchase of goods and services; information, advice and consultancy services in relation to all the aforesaid services | ACTIVE | — |
| 044 | Managed healthcare services being medical services in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; consultancy services in the field of medical information services; medical consultancy services in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; consultancy services in the field of biotechnology diagnostics and pharmacogenetics diagnostics medical testing; medical information, advice and consultancy services in the pharmaceutical and healthcare sectors; medical information, advice and consultancy services in relation to pharmacovigilance; information, advice and consultancy services in relation to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Agos Healthcare Limited
- Other trademarks owned by Agos Healthcare Limited
- Other trademarks owned by Agos Healthcare Limited
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AGOS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 11, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 11, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 23, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 23, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 3, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 21, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 21, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 21, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 21, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 21, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 19, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 19, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 19, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 26, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 26, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 26, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 20, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 20, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 19, 2020 | ALIE | ASSIGNED TO LIE | — |
| Sep 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 9, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 11, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 10, 2019 | NWAP | NEW APPLICATION ENTERED | — |